Chugai Says Sefaxersen Significantly Reduces Proteinuria in Phase III IgA Nephropathy Trial

By Public Technologies
  • Chugai Pharmaceutical announced on October 26, 2026, that Roche’s sefaxersen significantly reduced proteinuria in patients with IgA nephropathy.
  • Roche released interim Phase III IMAgINATION findings on October 23. Results were presented at ASN Kidney Week 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.